Radius Health to Present at the 36th Annual J.P. Morgan Healthcare Conference
January 05 2018 - 9:07AM
Radius Health, Inc. (Nasdaq:RDUS), today announced that President
and Chief Executive Officer, Jesper Høiland, will present a
corporate update at the 36th Annual J.P. Morgan Healthcare
Conference on Monday, January 8, 2018 at 11:00 a.m. PST at the
Westin St. Francis Hotel in San Francisco, California.
A live webcast of the presentation will be available by visiting
the Investors section of Radius' website at
http://ir.radiuspharm.com/events.cfm. A replay of the webcast will
be archived on Radius' website for 30 days following the
presentation.
About Radius Health
Radius is a science-driven fully integrated biopharmaceutical
company that is committed to developing and commercializing
innovative therapeutics in the areas of osteoporosis, oncology and
endocrine diseases. Radius' lead product, TYMLOS (abaloparatide)
injection, was approved by the U.S. Food and Drug Administration
for the treatment of postmenopausal women with osteoporosis at high
risk for fracture. Radius' Marketing Authorisation Application
(MAA) for abaloparatide-SC for the treatment of postmenopausal
women with osteoporosis is under regulatory review in Europe. The
Radius clinical pipeline includes an investigational abaloparatide
transdermal patch for potential use in osteoporosis; the
investigational drug elacestrant (RAD1901) for potential use in
hormone-receptor positive breast cancer; and the investigational
drug RAD140, a non-steroidal, selective androgen receptor modulator
(SARM) under investigation for potential use in hormone-receptor
positive breast cancer. For more information, please visit
www.radiuspharm.com, and follow us on Twitter and LinkedIn.
Investor Relations Contact:
Elhan Webb, CFA Email: ewebb@radiuspharm.comPhone:
617-551-4011
Radius Recycling (NASDAQ:RDUS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Radius Recycling (NASDAQ:RDUS)
Historical Stock Chart
From Apr 2023 to Apr 2024